|
Loading...
| ||||||||||||||
Recent Publications by Imutran Ltd. (a Novartis Pharma AG Company): |  | |
| Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates.
Transplantation in nonhuman primates, in particular using solid organs... | Imutran Ltd. (A Novartis Pharma AG Company), Cambridge CB2 2YP, UK. | Toxicology. 2005 Sep 15;213(1-2):1-12.
DOI Direct Link |
| Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor.
BACKGROUND: The expression of human complement regulators has been proved... | Imutran Ltd. (a Novartis Pharma AG Company), PO Box 399, Cambridge CB2 | Xenotransplantation. 2005 Mar;12(2):142-8.
DOI Direct Link |
| Reference values for clinical chemistry and clinical hematology parameters in cynomolgus monkeys.
BACKGROUND: In vivo xenotransplantation modeling in large animal species... | Imutran Ltd (A Novartis Pharma AG Company), Cambridge, UK. | Xenotransplantation. 2005 Jan;12(1):72-5.
DOI Direct Link |
| Reference values for clinical chemistry and clinical hematology parameters in baboons.
BACKGROUND: In vivo xenotransplantation modeling in large animal species... | Imutran Ltd (A Novartis Pharma AG Company), Cambridge CB2 2YP, UK. | Xenotransplantation. 2004 Nov;11(6):511-6.
DOI Direct Link |
| Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts.
To date, the best results in life-supporting pig-to-primate renal... | Transplant Unit, Imutran Ltd (A Novartis Pharma AG Company), Cambridge, | Xenotransplantation. 2003 Jul;10(4):300-10. |